That airspace extending upward from 700 feet above the surface within a 6.6-mile radius of Barrow/Wiley Post-Will Rogers Memorial Airport and within 4 miles each side of the Barrow Localizer back course extending from the 6.6-mile radius to 14.6 miles east of the airport; and that airspace extending upward from 1,200 feet above the surface within a 77-mile radius of the airport extending clockwise from the Barrow VORTAC 101° radial to the 240° radial and within the area bounded by a line beginning at the Barrow VORTAC 240° radial 20 miles west to 71° 13′ 15″ W to 71° 23′ 15″ N 157° 48′ W to 71° 25′ 15″ N 156° 55′ W to 71° 21′ 02″ N 156° 00′ 41″ W.

Issued in Anchorage, AK, on July 28, 1998.

Trent S. Cummings,
Acting Manager, Air Traffic Division, Alaskan Region.
[FR Doc. 98–20937 Filed 8–4–98; 8:45 am]
BILLING CODE 4910–13–P

DEPARTMENT OF COMMERCE

National Institute of Standards and Technology
15 CFR Part 280
[Docket Number: 980623159–8159–01]
RIN 0693–AB47
Implementation of the Fastener Quality Act
AGENCY: National Institute of Standards and Technology, United States Department of Commerce.
ACTION: Final rule; correction.
SUMMARY: In the June 30, 1998, Federal Register notice announcing the final rule and extension of implementation date for the Fastener Quality Act, important information was inadvertently omitted from one of the amendments, which has created ambiguity in the final rule. Accordingly, the Director of the National Institute of Standards and Technology (NIST) is publishing this notice to correct that amendment.
FOR FURTHER INFORMATION CONTACT: Dr. Subhas G. Malghan, FQA Program Manager, Technology Services, National Institute of Standards and Technology, Building 820, Room 306, Gaithersburg, MD 20899, telephone number (301) 975–5120.
SUPPLEMENTARY INFORMATION: In the Federal Register notice published on June 30, 1998, the letter (A) was inadvertently omitted from instruction number 4. Due to this omission, it was ambiguous whether subsections (B), (C), (D), and (E) were deleted from § 280.810(c)(3)(i). Since the items listed in these subsections still are required, NIST is publishing this correction to the final rule to eliminate the ambiguity.

The final rule published in the Federal Register on June 30, 1998 (63 FR 35507), on page 35508 in the first column, amendatory instruction number 4 is corrected to read as follows:

4. Section 280.810(c)(3)(i)(A) is revised to read as follows:

Robert E. Hehner,
Acting Deputy Director, National Institute of Standards and Technology.

BILLING CODE 3510–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
21 CFR Part 610
[Docket No. 97N–0449]
Revisions to the General Safety Test Requirements for Biological Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Direct final rule; Confirmation in part and withdrawal in part.
SUMMARY: The Food and Drug Administration (FDA) is confirming in part and withdrawing in part the provisions in the direct final rule that published in the Federal Register of April 20, 1998, to revise the general safety test (GST) requirements for biological products. FDA is confirming the part of the rule about which no significant adverse comment was received and withdrawing the part about which significant adverse comment was received.
DATES: The effective date for the revision of § 610.11(g)(1) published at 63 FR 19431, and (2) published at 63 FR 19430 (April 20, 1998) is September 2, 1998. The revised § 610.11(g)(1) (2) published at 63 FR 19430 (April 20, 1998) is withdrawn as of of August 5, 1998.
FOR FURTHER INFORMATION CONTACT: Dano B. Murphy, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852–1448, 301–827–6210.
SUPPLEMENTARY INFORMATION: FDA published a direct final rule on April 20, 1998 (63 FR 19399), that was intended to revise the GST requirements set forth in § 610.11 (21 CFR 610.11). In response to the direct final rule, the agency received significant adverse comment about § 610.11(g)(1), the provision of the rule that provides the administrative procedures for requesting an exemption from the GST requirements. The agency received no significant adverse comment about the addition of "cellular therapy products" to the list of products excepted from the GST in § 610.11(g)(1).
Under FDA’s direct final rule procedures, the receipt of any significant adverse comment will result in the withdrawal of the direct final rule; however, FDA may adopt as final any part of a direct final rule that can be severed and is not subject to significant adverse comment. Thus, the part of this direct final rule that received significant adverse comment can be severed and is being withdrawn, effective immediately. Comments received by the agency regarding the withdrawn portion of the rule will be applied to the corresponding portion of the companion proposed rule (63 FR 19431 and will be considered in developing a final rule using the usual Administrative Procedure Act notice-and-comment procedures.
FDA is confirming § 610.11(g)(1) of the direct final rule and adding "cellular therapy products” to the list of products excepted from the GST, effective September 2, 1998.

For the reasons set forth in the preamble, the revision of § 610.11(g)(2), published at 63 FR 19403 (April 20, 1998), is withdrawn and paragraph (g)(2) is reserved.
William K. Hubbard.
Associate Commissioner for Policy Coordination.

BILLING CODE 4160–01–F

DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 100
[CGD07–98–033]
RIN 2115–AE46
Special Local Regulations; St. Johns River, Jacksonville, Florida
AGENCY: Coast Guard, DOT.
ACTION: Final Rule.
SUMMARY: The Coast Guard is amending the permanent special local regulations for the Annual Greater Jacksonville Kingfish Tournament, by increasing the size of the No Wake Zone on the waters of the St. Johns River and establishing the annual date of the event during the...